

Oklahoma Board of Nursing
2501 N. Lincoln Blvd., Ste. 207
Oklahoma City, OK 73105
405-962-1800

CRNA Inclusionary Formulary

To be granted authority to select, order, obtain and administer drugs, Certified Registered Nurse Anesthetists (CRNAs) must hold a current Registered Nurse license, be recognized as a CRNA in Oklahoma and meet the continuing education requirements noted in the *Rules of the Oklahoma Board of Nursing*, specifically 485:10-18-2. Pursuant to 59 O.S. § 567.3a.10 [*Oklahoma Nursing Practice Act*], a CRNA is an Advanced Practice Registered Nurse who administers anesthesia in collaboration with a medical doctor, an osteopathic physician, a podiatric physician or a dentist licensed in this state and under conditions in which timely onsite consultation by such doctor, osteopath, podiatric physician or dentist is available. The Formulary Advisory Council has been established to develop and submit to the Board recommendations for an inclusionary formulary pursuant to 59 O.S. § 567.4b. [*Oklahoma Nursing Practice Act*].

Pursuant to 59 O.S. § 567.3a.10.h [*Oklahoma Nursing Practice Act*], “collaboration” means an agreement between a medical doctor, osteopathic physician, podiatric physician or dentist performing the procedure or directly involved with the procedure and the Certified Registered Nurse Anesthetist working jointly toward a common goal providing services for the same patient.

The following Board-approved *CRNA Inclusionary Formulary* lists drugs that may be ordered, selected, obtained or administered during the **perioperative** and **perioobstetrical** periods by CRNAs who have been granted authority by the Board to select, order, obtain, and administer drugs.

4:00 Antihistamine Drugs

- 4:04 First Generation Antihistamines
Diphenhydramine Hydrochloride
Promethazine Hydrochloride (see also 28:24.92 and 28:16.08.24)

12:00 Autonomic Drugs

- 12:04 Parasympathomimetic (Cholinergic) Agents
Neostigmine Bromide
Physostigmine Salicylate
Pyridostigmine Bromide
12:08 Anticholinergic Agents
12:08.08 Antimuscarinics/antispasmodics
Atropine
Glycopyrrolate
Ipratropium Bromide
Scopolamine

- 12:12 Sympathomimetic (Adrenergic) Agents
 - 12:12.04 α -Adrenergic Agonists
 - Midodrine
 - Phenylephrine
 - 12:12.08 β -Adrenergic Agonists
 - 12:12.08.04 Non-selective β -Adrenergic Agonists
 - Isoproterenol
 - 12:12.08.08 Selective β_1 -Adrenergic Agonists
 - Dobutamine
 - Dopamine
 - 12:12.08.12 Selective β_2 -Adrenergic Agonists
 - Albuterol/Levalbuterol
 - Formoterol
 - Indacaterol
 - Metaproterenol
 - Salmeterol
 - Terbutaline Sulfate
 - 12:12.12 α - and β -Adrenergic Agonists
 - Ephedrine
 - Epinephrine
 - Norepinephrine
 - Pseudoephedrine
- 12:16 Sympatholytic (Adrenergic Blocking) Agents
 - 12:16.04 α -Adrenergic Blocking Agents
 - 12:16.04.04 Non-selective α -Adrenergic Blocking Agents
 - Phentolamine
- 12:20 Skeletal Muscle Relaxants (all in this class approved including future new drugs)
 - 12:20.04 Centrally Acting Skeletal Muscle Relaxants
 - Carisoprodol
 - Cyclobenzaprine
 - Metaxalone
 - Methocarbamol
 - Tizanidine
 - 12:20.08 Direct-acting Skeletal Muscle Relaxants
 - Dantrolene Sodium
 - 12:20.12 GABA-derivative Skeletal Muscle Relaxants
 - Baclofen
 - 12:20.20 Neuromuscular Blocking Agents
 - Atracurium Besylate
 - Cisatracurium
 - Pancuronium Bromide
 - Rocuronium Bromide
 - Succinylcholine Chloride
 - Vecuronium Bromide

16:00 Blood Derivatives

Albumin Human
Plasma Protein Fraction

Blood and Blood Components (not in AHFS)**20:00 Blood Formation, Coagulation, and Thrombosis**

- 20:12 Antithrombotic Agents
 - 20:12.04 Anticoagulants
 - 20:12.04.12 Direct Thrombin Inhibitors
Bivalirudin
 - 20:12.04.16 Heparins
Enoxaparin
Heparin
- 20:28 Antihemorrhagic Agents
 - 20:28.08 Antiheparin Agents
Protamine Sulfate
 - 20:28.16 Hemostatics
Aminocaproic Acid
Tranexamic Acid (TXA)
 - 20:28.92 Antihemorrhagic Agents, Misc.
Idarucizumab
Andexanet Alfa

24:00 Cardiovascular Drugs

- 24:04 Cardiac Drugs
 - 24:04.04 Antiarrhythmic Agents
 - 24:04.04.04 Class Ia Antiarrhythmics
Disopyramide
Procainamide
Quinidine
 - 24:04.04.08 Class Ib Antiarrhythmics
Lidocaine
 - 24:04.04.20 Class III Antiarrhythmics
Amiodarone
 - 24:04.04.24 Class IV Antiarrhythmics
Adenosine
 - 24:04.08 Cardiotonic Agents
Digoxin
- 24:08 Hypotensive Agents
 - 24:08.16 Central α -Agonists
Clonidine
Methyldopa

- 24:08.20 Direct Vasodilators
 - Hydralazine
 - Sodium Nitroprusside
- 24:12 Vasodilating Agents
 - 24:12.08 Nitrates and Nitrites
 - Nitroglycerine
- 24:24 β -Adrenergic Blocking Agents
 - Atenolol
 - Esmolol Hydrochloride
 - Labetalol
 - Metoprolol
 - Nadolol
 - Propranolol
- 24:28 Calcium-Channel Blocking Agents
 - 24:28.08 Dihydropyridines
 - Nicardipine
 - Nifedipine
 - 24:28.92 Calcium-Channel Blocking Agents, Miscellaneous
 - Verapamil
- 24:32 Renin-Angiotensin-Aldosterone System Inhibitors
 - 24:32.04 Angiotensin-Converting Enzyme Inhibitors
 - Captopril
 - Enalaprilat/Enalapril

28:00 Central Nervous System Agents

- 28:04 General Anesthetics (all in this class approved including future new drugs)
 - 28:04.04 Barbiturates
 - Methohexital
 - 28:04.16 Inhalation Anesthetics
 - 28:04.92 General Anesthetics, Miscellaneous
 - Etomidate
 - Ketamine
 - Fospropofol
 - Propofol
- 28:08 Analgesics and Antipyretics
 - 28:08.04 Nonsteroidal Antiflammatory Agents
 - 28:08.04.08 Cyclooxygenase-2 (COX-2) Inhibitors
 - Celecoxib
 - 28:08.04.24 Salicylates
 - Aspirin
 - 28:08.04.92 Other Nonsteroidal Anti-inflammatory Agents
 - Ibuprofen
 - Indomethacin
 - Ketorolac
 - Meloxicam

- 28:08.08 Opiate Agonists (all in this class approved including future new drugs)
 - Codeine
 - Fentanyl
 - Hydrocodone
 - Hydromorphone
 - Levorphanol
 - Meperidine
 - Morphine
 - Remifentanyl
 - Sufentanyl Citrate
 - Tramadol
- 28:08.12 Opiate Partial Agonists (all in this class approved including future new drugs)
 - Buprenorphine
 - Butorphanol
 - Nalbuphine
- 28:08.92 Analgesics and Antipyretic, Miscellaneous
 - Acetaminophen
 - Sodium Thiosalicylate
- 28:10 Opiate Antagonists (all in this class approved including future new drugs)
 - Nalmefene
 - Naloxone
 - Naltrexone
- 28:12 Anticonvulsants
 - 28:12.04 Barbituates
 - Phenobarbital
 - 28:12.08 Benzodiazepines
 - Clonazepam (see also 28:24.08)
 - 28:12.12 Hydantoins
 - Ethotoin
 - Fosphenytoin
 - Phenytoin
 - 28:12.92 Anticonvulsants, Miscellaneous
 - Carbamazepine
 - Felbamate
 - Gabapentin
 - Lamotrigine
 - Magnesium Sulfate
 - Valproate/Divalproex
- 28:16 Psychotherapeutic Agents
 - 28:16.08 Antipsychotics
 - 28:16.08.04 Atypical Antipsychotics
 - 28:16.08.08 Butyrophenones
 - Haloperidol

- 28:16.08.24 Phenothiazines
 - Perphenazine
 - Prochlorperazine
- 28:20 Anorexigenic Agents and Respiratory and CNS Stimulants
 - 28:20.32 Respiratory and CNS Stimulants
 - Caffeine/Caffeine and Sodium Benzoate
 - Doxapram
 - 28:24 Anxiolytics, Sedatives, and Hypnotics
 - 28:24.04 Barbiturates (all in this class approved including future new drugs)
 - Phenobarbital
 - 28:24.08 Benzodiazepines (all in this class approved including future new drugs)
 - Alprazolam
 - Chlordiazepoxide
 - Diazepam
 - Lorazepam
 - Midazolam
 - Remimazolam
 - Temazepam
 - 28:24.92 Anxiolytics, Sedatives, and Hypnotics, Miscellaneous
 - Dexmedetomidine
 - Hydroxyzine
 - Promethazine
 - 28:36 Antiparkinsonian Agents
 - 28:36.08 Anticholinergic Agents
 - Benztropine Mesylate
 - 28:92 Central Nervous System Agents, Miscellaneous
 - Flumazenil

36:00 Diagnostic Agents

- 36:40 Kidney Function
 - Indigo Carmine (Indigotindisulfonate)
- 36:56 Myasthenia Gravis
 - Edrophonium Chloride

40:00 Electrolytic, Caloric, and Water Balance

- 40:08 Alkalinizing Agents
 - Citrates (i.e., potassium citrate and citric acid, sodium citrate and citric acid, tricitrates)
 - Sodium Bicarbonate
 - Sodium Lactate
- 40:12 Replacement Preparations
 - Calcium Salts
 - Dextran 40

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23; 5/28/24

Page 6 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

P: /Administration/Executive/Policies/Practice/P-50A CRNA Inclusionary Formulary

- Electrolyte Solutions
- Hetastarch
- Potassium Supplements
- Sodium Chloride
- 40:20 Caloric Agents
 - Dextrose
 - Invert Sugar
- 40:24 Salt and Sugar Substitutes
- 40:28 Diuretics
 - 40:28.08 Loop Diuretics
 - Bumetanide
 - Furosemide
 - 40:28.12 Osmotic Diuretics
 - Mannitol
 - 40:28.20 Thiazide Diuretics
 - Chlorothiazide

48:00 Respiratory Tract Agents (all in this class approved including future new drugs)

- 48:08 Antitussives
 - Benzonatate
 - Codeine
 - Dextromethorphan
 - Hydrocodone
- 48:16 Expectorants
 - Guaifenesin
 - Potassium Iodide (see also 68:36.08)
- 48:24 Mucolytic Agents
 - Acetylcysteine (see also 92:12)

52:00 Eye, Ear, Nose, and Throat (EENT) Preparations

- 52:16 Local Anesthetics
 - Benzocaine
 - Dyclonine
 - Proparacaine
 - Tetracaine
- 52:32 Vasoconstrictors
 - Epinephrine
 - Naphazoline
 - Oxymetazoline
 - Phenylephrine
 - Propylhexedrine
 - Tetrahydrolozine
- 52:40 Antiglaucoma Agents
 - 52:40.12 Carbonic Anhydrase Inhibitors
 - Acetazolamide

56:00 Gastrointestinal Drugs

56:04 Antacids and Adsorbents

Aluminum Carbonate
Aluminum Hydroxide
Aluminum Phosphate
Antacids
Calcium Carbonate
Charcoal, Activated
Dihydroxyaluminum Aminoacetate
Dihydroxyaluminum Sodium Carbonate
Magaldrate
Magnesium Carbonate
Magnesium Hydroxide
Magnesium Oxide
Magnesium Trisilicate
Sodium Bicarbonate

56:22 Antiemetics

56:22.08 Antihistamines

Dimenhydrinate
Meclizine
Prochlorperazine
Trimethobenzamide

56:22.20 5-HT₃ Receptor Antagonists

Dolasetron
Granisetron
Ondansetron

56:22.92 Antiemetics, Miscellaneous

Amisulpride

56:28 Antiulcer Agents and Acid Suppressants

56:28.12 Histamine H₂-Antagonists

Cimetidine
Famotidine
Nizatidine

56:28.32 Protectants

Sucralfate

56:28.36 Proton-pump Inhibitors

Dexlansoprazole
Esomeprazole
Lansoprazole
Omeprazole
Pantoprazole
Rabeprazole

56:32 Prokinetic Agents

Metoclopramide

68:00 Hormones and Synthetic Substitutes

68:04 Adrenals (all in this class approved including future new drugs)

Beclomethasone
Betamethasone
Cortisone Acetate
Dexamethasone
Fludrocortisone
Flunisolide
Hydrocortisone
Methyprednisolone
Prednisolone
Prednisone
Triamcinolone

68:20 Antidiabetic Agents

68:20.08 Insulins

68:20.08.04 Rapid-acting Insulins

Insulin Aspart
Insulin Glulisine
Insulin Lispro

68:20.08.08 Short-acting Insulins

Insulin Human
Insulin Isophane

68:20.08.16 Long-acting Insulins

Insulin Glargine

68:20.20 Sulfonylureas

Glimepiride
Glipizide
Glyburide
Tolazamide
Tolbutamide

68:22 Antihypoglycemic Agents

68:22.12 Glycogenolytic Agents

Glucagon

68:28 Pituitary

Corticotropin
Desmopressin
Vasopressin

68:44 Renin-Angiotensin-Aldosterone System (RAAS)

Angiotensin II

72:00 Local Anesthetics (all in this class approved including future new drugs)

Articaine
Bupivacaine
Chloroprocaine
Lidocaine
Mepivacaine
Prilocaine

Procaine
Ropivacaine
Tetracaine

76:00 Oxytocics

Carboprost Tromethamine
Dinoprostone
Ergonovine/Methergonovine
Oxytocin

84:00 Skin and Mucous Membrane Agents

84:04 Anti-infective

84:04.92 Local Anti-Infectives, Miscellaneous
Chlorhexidine gluconate

84:08 Antipruritics and Local Anesthetics (all in this class approved including future new drugs)

Benzocaine
Dibucaine
Doxepin
Ethyl Chloride
Phenazopyridine
Pramoxine

86:00 Smooth Muscle Relaxants

86:16 Respiratory Smooth Muscle Relaxants

Aminophylline
Theophyllines

92:00 Miscellaneous Therapeutic Agents

92:12 Antidotes

Acetylcysteine
Methylene Blue
Sugammadex

NOTE: ACLS Algorithm medications are approved and listed according to the AHFS classification system.

Regulatory Authority:

59 O.S. §567.4b.

Reference:

American Hospital Formulary Service®. *AHFS Drug Information* (2022). Published by Authority of the Board of the American Society of Health-System Pharmacists®, Bethesda, MD.

Board Approved: 1/20/98

OBN Policy/Guideline - #P-50A

Board Reviewed w/o Revision: 1/28/99; 5/23/06; 5/23/23; 5/28/24

Page 10 of 10

Board Revised: 9/30/99; 5/25/01; 5/28/02; 5/27/03; 5/25/04; 5/24/05; 5/29/07; 5/27/08; 5/19/09; 5/25/10; 7/26/11; 5/22/12; 5/28/13; 7/14/14; 5/19/15; 5/24/16; 7/25/17; 5/22/18; 5/21/19; 11/10/20; 5/25/21; 7/26/22

P: /Administration/Executive/Policies/Practice/P-50A CRNA Inclusionary Formulary